33 research outputs found
Mejoramiento del arroz de secano para América Latina
Improving upland rice for Latin America The ecosystems for upland rice in Latin America and the Caribbean and their limitations for rice cultivation are analyzed. The sites where the CIAT rice program and the collaborative project that the Center carries out with the French Agricultural Research Centre for International Development (CIRAD) evaluate and select genetic materials for upland conditions are also described, as well as the conventional genetic improvement activities carried out by CIAT since 1981 and those carried out by CIRAD since 1996. These activities include population development through population improvement and recurrent selection. The advances made so far are reported. As a result of these research projects, lines have been developed that present high yield potential and new commercial varieties have been released that have been quickly adopted by farmers. This has allowed the opening of new agricultural frontiers in Colombia’s Eastern Plains, and northern coast regions. In Brazil, the production of upland rice has been stimulated and, in Bolivia, alternatives to upland rice cultivation are being offered.Se analizan los ecosistemas para el arroz de secano de América Latina y el Caribe, las limitaciones que presentan para el cultivo del arroz, y los sitios donde se evalúan y seleccionan materiales genéticos de arroz de secano del Programa de Arroz del CIAT y del proyecto de cooperación con el Centro de Cooperación Internacional en Investigación Agrícola para el Desarrollo (CIRAD), de Francia. Se describen también las actividades de mejoramiento genético convencional desarrolladas por el CIAT desde 1981, y las que realizó el CIRAD desde 1996, es decir, desarrollo de poblaciones mediante la implementación del mejoramiento poblacional y su mejora mediante la selección recurrente. También se presentan algunos datos de los avances obtenidos. Como resultado de estos proyectos de investigación se han desarrollado líneas de elevado potencial productivo y se han liberado nuevas variedades comerciales rápidamente adoptadas por los agricultores. Con ellas se han abierto nuevas fronteras agrícolas en los Llanos Orientales y en la costa norte de Colombia, se ha estimulado la producción del arroz de secano en Brasil y se han ofrecido alternativas al cultivo de arroz de secano en Bolivia
Uso de selección recurrente en combinación con cultivo de anteras en el programa de arroz de riego del CIAT
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.
OBJECTIVE
To evaluate the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital wards.
DESIGN
Randomised controlled, adaptive, open label clinical trial.
SETTING
28 hospitals in Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, and US.
PARTICIPANTS
465 adults admitted to hospital wards with covid-19 and increased D-dimer levels were recruited between 29 May 2020 and 12 April 2021 and were randomly assigned to therapeutic dose heparin (n=228) or prophylactic dose heparin (n=237).
INTERVENTIONS
Therapeutic dose or prophylactic dose heparin (low molecular weight or unfractionated heparin), to be continued until hospital discharge, day 28, or death.
MAIN OUTCOME MEASURES
The primary outcome was a composite of death, invasive mechanical ventilation, non-invasive mechanical ventilation, or admission to an intensive care unit, assessed up to 28 days. The secondary outcomes included all cause death, the composite of all cause death or any mechanical ventilation, and venous thromboembolism. Safety outcomes included major bleeding. Outcomes were blindly adjudicated.
RESULTS
The mean age of participants was 60 years; 264 (56.8%) were men and the mean body mass index was 30.3 kg/m2. At 28 days, the primary composite outcome had occurred in 37/228 patients (16.2%) assigned to therapeutic heparin and 52/237 (21.9%) assigned to prophylactic heparin (odds ratio 0.69, 95% confidence interval 0.43 to 1.10; P=0.12). Deaths occurred in four patients (1.8%) assigned to therapeutic heparin and 18 patients (7.6%) assigned to prophylactic heparin (0.22, 0.07 to 0.65; P=0.006). The composite of all cause death or any mechanical ventilation occurred in 23 patients (10.1%) assigned to therapeutic heparin and 38 (16.0%) assigned to prophylactic heparin (0.59, 0.34 to 1.02; P=0.06). Venous thromboembolism occurred in two patients (0.9%) assigned to therapeutic heparin and six (2.5%) assigned to prophylactic heparin (0.34, 0.07 to 1.71; P=0.19). Major bleeding occurred in two patients (0.9%) assigned to therapeutic heparin and four (1.7%) assigned to prophylactic heparin (0.52, 0.09 to 2.85; P=0.69).
CONCLUSIONS
In moderately ill patients with covid-19 and increased D-dimer levels admitted to hospital wards, therapeutic heparin was not significantly associated with a reduction in the primary outcome but the odds of death at 28 days was decreased. The risk of major bleeding appeared low in this trial.
TRIAL REGISTRATION
ClinicalTrials.gov NCT04362085
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial
Objectives:
To determine the effect of therapeutic anticoagulation, with low molecular weight heparin (LMWH) or unfractionated heparin (UFH, high dose nomogram), compared to standard care in hospitalized patients admitted for COVID-19 with an elevated D-dimer on the composite outcome of intensive care unit (ICU) admission, non-invasive positive pressure ventilation, invasive mechanical ventilation or death up to 28 days.
Trial design:
Open-label, parallel, 1:1, phase 3, 2-arm randomized controlled trial
Participants:
The study population includes hospitalized adults admitted for COVID-19 prior to the development of critical illness. Excluded individuals are those where the bleeding risk or risk of transfusion would generally be considered unacceptable, those already therapeutically anticoagulated and those who have already have any component of the primary composite outcome. Participants are recruited from hospital sites in Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, and the United States of America.
The inclusion criteria are:
1)
Laboratory confirmed COVID-19 (diagnosis of SARS-CoV-2 via reverse transcriptase polymerase chain reaction as per the World Health Organization protocol or by nucleic acid based isothermal amplification) prior to hospital admission OR within first 5 days (i.e. 120 hours) after hospital admission;
2)
Admitted to hospital for COVID-19;
3)
One D-dimer value above the upper limit of normal (ULN) (within 5 days (i.e. 120 hours) of hospital admission) AND EITHER:
a.
D-Dimer ≥2 times ULN OR
b.
D-Dimer above ULN and Oxygen saturation ≤ 93% on room air;
4)
> 18 years of age;
5)
Informed consent from the patient (or legally authorized substitute decision maker).
The exclusion criteria are:
1)
pregnancy;
2)
hemoglobin <80 g/L in the last 72 hours;
3)
platelet count <50 x 109/L in the last 72 hours;
4)
known fibrinogen <1.5 g/L (if testing deemed clinically indicated by the treating physician prior to the initiation of anticoagulation);
5)
known INR >1.8 (if testing deemed clinically indicated by the treating physician prior to the initiation of anticoagulation);
6)
patient already prescribed intermediate dosing of LMWH that cannot be changed (determination of what constitutes an intermediate dose is to be at the discretion of the treating clinician taking the local institutional thromboprophylaxis protocol for high risk patients into consideration);
7)
patient already prescribed therapeutic anticoagulation at the time of screening [low or high dose nomogram UFH, LMWH, warfarin, direct oral anticoagulant (any dose of dabigatran, apixaban, rivaroxaban, edoxaban)];
8)
patient prescribed dual antiplatelet therapy, when one of the agents cannot be stopped safely;
9)
known bleeding within the last 30 days requiring emergency room presentation or hospitalization;
10)
known history of a bleeding disorder of an inherited or active acquired bleeding disorder;
11)
known history of heparin-induced thrombocytopenia;
12)
known allergy to UFH or LMWH;
13)
admitted to the intensive care unit at the time of screening;
14)
treated with non-invasive positive pressure ventilation or invasive mechanical ventilation at the time of screening;
15)
Imminent death according to the judgement of the most responsible physician;
16)
enrollment in another clinical trial of antithrombotic therapy involving hospitalized patients.
Intervention and comparator:
Intervention: Therapeutic dose of LMWH (dalteparin, enoxaparin, tinzaparin) or high dose nomogram of UFH. The choice of LMWH versus UFH will be at the clinician’s discretion and dependent on local institutional supply.
Comparator: Standard care [thromboprophylactic doses of LMWH (dalteparin, enoxaparin, tinzaparin, fondaparinux)] or UFH. Administration of LMWH, UFH or fondaparinux at thromboprophylactic doses for acutely ill hospitalized medical patients, in the absence of contraindication, is generally considered standard care.
Main outcomes:
The primary composite outcome of ICU admission, non-invasive positive pressure ventilation, invasive mechanical ventilation or death at 28 days.
Secondary outcomes include (evaluated up to day 28):
1.
All-cause death
2.
Composite of ICU admission or all-cause death
3.
Composite of mechanical ventilation or all-cause death
4.
Major bleeding as defined by the ISTH Scientific and Standardization Committee (ISTH-SSC) recommendation;
5.
Red blood cell transfusion (>1 unit);
6.
Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate;
7.
Renal replacement therapy;
8.
Hospital-free days alive;
9.
ICU-free days alive;
10.
Ventilator-free days alive;
11.
Organ support-free days alive;
12.
Venous thromboembolism (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);
13.
Arterial thromboembolism (defined as suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);
14.
Heparin induced thrombocytopenia;
15.
Trajectories of COVID-19 disease-related coagulation and inflammatory biomarkers.
Randomisation:
Randomisation will be stratified by site and age (>65 versus ≤65 years) using a 1:1 computer-generated random allocation sequence with variable block sizes. Randomization will occur within the first 5 days (i.e. 120 hours) of participant hospital admission. However, it is recommended that randomization occurs as early as possible after hospital admission. Central randomization using an interactive web response system will ensure allocation concealment.
Blinding (masking):
No blinding involved. This is an open-label trial.
Numbers to be randomised (sample size):
462 patients (231 per group) are needed to detect a 15% risk difference, from 50% in the control group to 35% in the experimental group, with power of 90% at a two-sided alpha of 0.05.
Trial Status:
Protocol Version Number 1.4. Recruitment began on May 11th, 2020. Recruitment is expected to be completed March 2022. Recruitment is ongoing.
Trial registration:
ClinicalTrials.gov Identifier:
NCT04362085
Date of Trial Registration: April 24, 2020
Full protocol:
The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.Other UBCNon UBCReviewedFacult
Diversity and contact : immigration and social integration in German cities
EHRA Scientific Committee Task Force: Bulent Gorenek, Antonio Pelliccia, Emelia J. Benjamin, Giuseppe Boriani, Harry J. Crijns, Richard I. Fogel, Isabelle C. Van Gelder, Martin Halle, Gulmira Kudaiberdieva, Deirdre A. Lane, Torben Bjerregaard Larsen, Gregory Y. H. Lip, Maja-Lisa Løchen, Francisco Marín, Josef Niebauer, Prashanthan Sanders, Lale Tokgozoglu, Marc A. Vos, and David R. VanWagone
Characteristics of Aspergillus fumigatus in Association with Stenotrophomonas maltophilia in an In Vitro Model of Mixed Biofilm
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial
International audienc
Правда коммунизма. 1958. № 068
Scientific statement of the transnational alliance for regenerative therapies in cardiovascular syndromes (TACTICS) international group for the comprehensive cardiovascular application of regenerative medicinal products